Baillie Gifford & Co
MED icon

Baillie Gifford & Co’s Medifast MED Stock Holding History

Baillie Gifford & Co’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-154
Closed -$16K – 386
2023
Q1 		$16K Buy
154
+16
+12% +$1.77K ﹤0.01% 360
2022
Q4 		$15.9K Buy
138
+17
+14% +$1.98K ﹤0.01% 364
2022
Q3 		$13K Sell
121
-12
-9% -$1.72K ﹤0.01% 382
2022
Q2 		$24K Buy
133
+13
+11% +$2.33K ﹤0.01% 324
2022
Q1 		$20K Buy
120
+10
+9% +$1.89K ﹤0.01% 365
2021
Q4 		$23K Hold
110
– – ﹤0.01% 362
2021
Q3 		$21K Sell
110
-19
-15% -$4.67K ﹤0.01% 368
2021
Q2 		$37K Sell
129
-5
-4% -$1.35K ﹤0.01% 302
2021
Q1 		$28K Buy
+134
New +$32.1K ﹤0.01% 305

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Baillie Gifford & Co's MED Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Medifast (MED) in Q2 2023, closing a stake of 154 shares — an estimated $16K sold.

Baillie Gifford & Co first reported a position in MED in Q1 2021 and held it in 9 quarters. The position peaked at $37K in Q2 2021. 236 funds tracked by Wall St. Rank hold MED as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Medifast position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 154 Medifast shares in Q2 2023, an estimated $16K.
  • Baillie Gifford & Co first reported a position in Medifast in Q1 2021 and held it in 9 quarters.
  • Baillie Gifford & Co's Medifast position peaked at $37K in Q2 2021.
  • 236 funds tracked by Wall St. Rank held Medifast as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.